2 unknown. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Unknown 2 |
| Phase 2 | 1 | Unknown 1 |
Follow AtheroGenics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ANDES-AGI-1067 as a Novel Antidiabetic Agent Evaluation Study Placebo, AGI-1067 - Diabetes | Phase 2 / Phase 3 | Unknown | AtheroGenics | 1012 | 2007-08-01 | 2008-02-06 |
| ARISE - Aggressive Reduction of Inflammation Stops Events AGI-1067 - Atherosclerosis, Coronary Artery Disease | Phase 3 | Unknown | AtheroGenics | 6000 | 2003-06-01 | 2006-10-03 |
Angina, Unstable (1) · Atherosclerosis (1) · Coronary Artery Disease (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Myocardial Infarction (1)
succinobucol (2)
South Africa (2) · United States (2) · Bosnia and Herzegovina (1) · Canada (1) · Georgia (1) · India (1) · North Macedonia (1) · Serbia and Montenegro (1) · Ukraine (1) · United Kingdom (1)
Eric Klug, MD (1) · Jean-Claude Tardif, MD (1) · John McMurray, MD (1) · Marc A Pfeffer, MD (1) · Walker Long, MD (1)